Literature DB >> 21262441

APS--controversies in diagnosis and management, critical overview of current guidelines.

Vittorio Pengo1.   

Abstract

Because the diagnosis of antiphospholipid syndrome is based on laboratory data, performance and interpretation of such tests is essential. Positivity in a single test among Lupus Anticoagulant (LA), anti cardiolipin (aCL) and anti β2-glycoprotein I (aβ2GPI) antibodies calls APS diagnosis into question. Conversely, triple positivity is strongly associated to thrombosis and pregnancy morbidity. A new era in studying APS should take into account different antiphospholipid antibodies profiles. Clinical studies on groups of patients that are homogeneous in terms of laboratory tests will provide information on the real risk of patients and on the real effect of therapeutic interventions.
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21262441     DOI: 10.1016/S0049-3848(11)70014-7

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

1.  Leg ulcers in antiphospholipid syndrome secondary to systemic lupus erythematosus treated with intravenous immunoglobulin.

Authors:  Guida Santos; Alexandre João; Lourdes Sousa
Journal:  J Dermatol Case Rep       Date:  2014-06-30

2.  8-isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: a pilot study.

Authors:  Savino Sciascia; Dario Roccatello; Maria Tiziana Bertero; Debora Di Simone; Domenico Cosseddu; Antonella Vaccarino; Mario Bazzan; Daniela Rossi; Cesar Garcia-Fernandez; Leticia Ceberio; Stefania Stella; Elisa Menegatti; Simone Baldovino
Journal:  Inflamm Res       Date:  2012-05-26       Impact factor: 4.575

3.  Management of very high risk pregnancy with secondary anti-phospholipid syndrome and triple positivity to the anti-phospholipid antibodies.

Authors:  Hannah L Rose; Wai Khoon Ho
Journal:  J Thromb Thrombolysis       Date:  2014-11       Impact factor: 2.300

4.  Presence of antiphospholipid antibody is a risk factor in thrombotic events in patients with antiphospholipid syndrome or relevant diseases.

Authors:  Koji Habe; Hideo Wada; Takeshi Matsumoto; Kohshi Ohishi; Makoto Ikejiri; Kimiko Matsubara; Tatsuhiko Morioka; Yuki Kamimoto; Tomoaki Ikeda; Naoyuki Katayama; Tsutomu Nobori; Hitoshi Mizutani
Journal:  Int J Hematol       Date:  2013-02-03       Impact factor: 2.490

5.  Renal transplantation dramatically reduces IgA anti-beta-2-glycoprotein I antibodies in patients with endstage renal disease.

Authors:  Manuel Serrano; Jose Angel Martínez-Flores; Maria José Castro; Florencio García; David Lora; Dolores Pérez; Esther Gonzalez; Estela Paz-Artal; Jose M Morales; Antonio Serrano
Journal:  J Immunol Res       Date:  2014-04-10       Impact factor: 4.818

6.  Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers.

Authors:  Dirk Roggenbuck; Maria Orietta Borghi; Valentina Somma; Thomas Büttner; Peter Schierack; Katja Hanack; Claudia Grossi; Caterina Bodio; Paolo Macor; Philipp von Landenberg; Francesco Boccellato; Michael Mahler; Pier Luigi Meroni
Journal:  Arthritis Res Ther       Date:  2016-05-21       Impact factor: 5.156

7.  Profiles of criteria and non-criteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome.

Authors:  Ilan Volkov; Luciana Seguro; Elaine P Leon; László Kovács; Dirk Roggenbuck; Peter Schierack; Boris Gilburd; Andrea Doria; Maria G Tektonidou; Nancy Agmon-Levin
Journal:  Auto Immun Highlights       Date:  2020-05-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.